Expert consensus on the combination of anti-EGFR monoclonal antibodies and immune checkpoint inhibitors in the treatment of head and neck squamous cell carcinoma (2025 edition)

Expert consensus on the combination of anti-EGFR monoclonal antibodies and immune checkpoint inhibitors in the treatment of head and neck squamous cell carcinoma (2025 edition)

Head and neck squamous cell carcinoma (HNSCC) is the most common type of head and neck cancer, and its treatment prognosis remains suboptimal. Although the survival of HNSCC patients has improved with the widespread use of anti-epidermal growth factor receptor (EGFR) monoclonal antibodies and immune...

Full description

Saved in:
Bibliographic Details
Main Author: XUE Liqiong, XU Tingting, GUO Ye, HU Chaosu
Format: Article
Language:English
Published: Editorial Office of China Oncology 2025-05-01
Series:Zhongguo aizheng zazhi
Subjects:
|head and neck squamous cell carcinoma|anti-epidermal growth factor receptor monoclonal antibodies|immune checkpoint inhibitors|combination treatment|safety|expert consensus
Online Access:https://www.china-oncology.com/fileup/1007-3639/PDF/1749540851103-2132024817.pdf
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items